ClinicalTrials.gg
CompletedNCT06003088Updated Aug 24, 2023

Relative Bioavailability and Pharmacodynamics of HSK7653 in Healthy Volunteers

A Phase 1 interventional study of HSK7653(5mg) and HSK7653(25mg) in Healthy, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2022, registered Jan 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To investigate the relative bioavailability of HSK7653(5mg) given as formulation A versus formulation B.

To investigate the relative bioavailability of HSK7653(25mg) given as formulation A versus formulation B.

To investigate safety and pharmacodynamics of two doses of HSK7653 in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects, age ≥18 years old,with appropriate sex ratio;
  2. A total body weight ≥40 kg for females and ≥50 kg for males; of 19 to 26 kg/m\^2(inclusive);
  3. Subjects(and their partners) volunteered to use effective physical , had no plans to have children or donate sperm/eggs from 14 days before the first dose to 6 months after the last dose;
  4. Evidence of a personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who are allergic to two or more medicine, foods or pollens or have a history of allergy to the product and the related compounds;
  2. Have a history of severe unconscious hypoglycemia;
  3. Clinical evidence or history of any of the following diseases:

    • Inflammatory bowel disease, gastritis, ulcers, bile duct stones, or gastrointestinal bleeding
    • Major gastrointestinal surgery (e.g., gastrectomy, gastrostomy, or enterectomy)
    • Pancreatic injury or pancreatitis
    • Abnormal liver function tests (such as , AST, serum ) , indicating liver disease or liver injury
    • Renal insufficiency
    • Urinary tract obstruction or difficulty in bladder emptying;
  4. Evidence or history of chronic or serious diseases of the blood system, circulatory system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, mental disorders, metabolic disorders, or any other diseases that may affect the results of the study;
  5. Serious trauma and surgery within 3 month prior to Screening;
  6. Use of vaccines within 1 month prior to dosing;
  7. Use of prescription within 1 month prior to dosing,or use of nonprescription drugs(i.e. vitamins and herbal medicines)within 14 days prior to dosing;
  8. Participation in another trial with an investigational drug or instrument within 3 months prior to dosing and for the duration of the study;
  9. History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of Screening.
  10. Use of alcohol during the trial,or have a positive result for alcohol breath test;
  11. Smoking ≥5 cigarettes per day within 3 months prior to Screening;
  12. Blood donation or loss of blood for≥ 400 mL or received blood transfusion or use of blood products within 3 months prior to Screening, or blood donation program for the duration of the study and for 1 month after the trial;
  13. Drinking excessive amounts of tea, coffee, and/or caffeinated beverages daily (average more than 8 cups per day,1 cup =250 mL) within 3 months prior to Screening;
  14. Use of grapefruit, pomelo, dragon fruit, mango and other fruits or related products that may affect metabolic enzymes within 7 days prior to dosing;
  15. Use of products containing alcohol within 48 hours prior to dosing and for the duration of the study;
  16. Smoking or using any tobacco product within 48 hours prior to dosing and for the duration of the study;
  17. Strenuous activities within 48 hours prior to dosing;
  18. Use of chocolate, food or beverages containing caffeine or xanthine within 48 hours prior to dosing;
  19. History of drug abuse or drug dependence;
  20. (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody, or Treponema pallidum antibody (TPPA) has a positive result;
  21. Any physical examination, vital signs, or clinical laboratory measurement abnormalities during screening, or Screening 12-lead ECG demonstrating >440 msec for males and >420 msec for females,or FPG\< 3.9mmol/L or > 6.1mmol/L;
  22. Pregnant or lactating women, or female subjects whose pregnancy test results are positive;
  23. Lactose intolerant;
  24. Subjects who have a history of fainting needles and blood, or who cannot tolerate venipuncture blood sampling;
  25. Difficulty in swallowing tablets and capsules;
  26. Special dietary requirements (e.g. vegetarians) or cannot follow a uniform diet during the trial;
  27. Unable to cooperate to complete the study due to other reasons, or in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    HSK7653(5mg) Sequence A(Formulation A + Formulation B)

    Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation B.

    Drug: HSK7653(5mg)

  • Experimental
    HSK7653(5mg) Sequence B(Formulation B + Formulation A)

    Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(5mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(5mg) Formulation A.

    Drug: HSK7653(5mg)

  • Experimental
    HSK7653(25mg) Sequence A(Formulation A + Formulation B)

    Participants will receive a single oral dose of treatment 1: Formulation A followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation B.

    Drug: HSK7653(25mg)

  • Experimental
    HSK7653(25mg) Sequence B(Formulation B + Formulation A)

    Participants will receive a single oral dose of treatment 1: Formulation B followed by a washout period of at least 36 days from first dose of HSK7653(25mg). After the washout period, participants will receive a single oral dose of Treatment 2: HSK7653(25mg) Formulation A.

    Drug: HSK7653(25mg)

Interventions

  • Participants will receive a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(5mg) Formulation A Or a single oral dose of HSK7653(5mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

    Also known as: HSK7653

  • Participants will receive a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 Period 1. Depending on what Formulation was received on Day 1 Period 1, participants will receive either a single oral dose of HSK7653(25mg) Formulation A Or a single oral dose of HSK7653(25mg) Formulation B on Day 1 of Period 2. Each period lasts for 15 days.

    Also known as: HSK7653

06

What researchers measure

Primary outcomes

  1. Relative bioavailability (F)

    To Evaluate Relative Bioavailability (F) of Two Doses of HSK7653 in Healthy Volunteers. Relative bioavailability of HSK7653(5mg) given as formulation A versus formulation B=AUC(0-t)(HSK7653(5mg) Formulation A)/AUC(0-t)(HSK7653(5mg) Formulation B). Relative bioavailability of HSK7653(25mg) given as formulation A versus formulation B=AUC(0-t)(HSK7653(25mg) Formulation A)/AUC(0-t)(HSK7653(25mg) Formulation B).

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  2. AUC(0-t)

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  3. AUC(0-∞)

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  4. Cmax

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  5. Tmax

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  6. t1/2

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  7. λz

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  8. Vd/F

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  9. CL/F

    The pharmacokinetic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

Secondary outcomes

  1. The Safety of HSK7653

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: From First dose until Follow up visit, assessed up to 3 months.

  2. AUEC(0-last)

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  3. ECmax

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  4. ETmax

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

  5. DPP-4(WAI-2W)

    The pharmacodynamic parameters of HSK7653 in plasma

    Time frame: Pre-dose,0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168 and 336 hours post-dose.

07

Study locations

1 site
  • The First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
    Shenyang, Liaoning, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Aug 2022, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Aug 21, 2023
StartActual
Jun 15, 2022
Primary completionActual
Aug 12, 2022
CompletionActual
Sep 9, 2022
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06003088
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jun 15, 2022
Primary completion
Aug 12, 2022
Completion
Sep 9, 2022
Last update
Aug 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK7653

Start the discussion